Menu Content/Inhalt
Search  

PRESS RELEASES


   Order     Display # 
Date Item Title
09-Feb-2010 Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C -
30-Apr-2009 Clinical Update – Debio 025 in Hepatitis C - Debiopharm starts phase IIb study after record time patient randomisation
28-Apr-2009 Clinical Update – Debio 025 in Hepatitis C - Debiopharm presents promising phase IIa results showing potent antiviral activity
23-Jan-2009 Clinical Update – Debio 025 in Hepatitis C - Debiopharm starts phase IIb triple therapy study, a promising therapeutic avenue
28-Apr-2008 Clinical Update – Debio 025 in Hepatitis C - Presentation of Phase IIa Efficacy Results
 
< Prev 1 2 Next >
Results 1 - 5 of 9